JP2019112416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112416A5
JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
exemestane
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026073A
Other languages
English (en)
Japanese (ja)
Other versions
JP6860949B2 (ja
JP2019112416A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112416A publication Critical patent/JP2019112416A/ja
Publication of JP2019112416A5 publication Critical patent/JP2019112416A5/ja
Application granted granted Critical
Publication of JP6860949B2 publication Critical patent/JP6860949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026073A 2013-05-03 2019-02-15 癌の処置方法 Active JP6860949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016512076A Division JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Publications (3)

Publication Number Publication Date
JP2019112416A JP2019112416A (ja) 2019-07-11
JP2019112416A5 true JP2019112416A5 (enExample) 2019-09-19
JP6860949B2 JP6860949B2 (ja) 2021-04-21

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (enExample)
JP (2) JP2016522188A (enExample)
KR (1) KR102337598B1 (enExample)
CN (1) CN105492007A (enExample)
HK (1) HK1223547A1 (enExample)
WO (1) WO2014179738A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004092A1 (en) * 2015-06-29 2017-01-05 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
JP7397011B2 (ja) * 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ, インコーポレイテッド S1p1受容体に関連する状態を治療する方法
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533053A (ja) * 2005-03-11 2008-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド ヒストン脱アセチル化酵素阻害剤は、がん細胞を上皮増殖因子受容体阻害剤に対して感受性にする
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
MX2010009844A (es) * 2008-03-07 2010-09-30 Pfizer Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
GEP201706612B (en) * 2011-09-02 2017-02-10 Novamedica Llc Methods for the treatment of breast cancer

Similar Documents

Publication Publication Date Title
EP2879523B1 (en) Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)
JP2022121594A5 (enExample)
RU2022102537A (ru) Нейроактивные стероиды, их композиции и применения
JP2023107883A5 (enExample)
JP2022552187A5 (enExample)
JP2023153863A (ja) 15-hepeを含む組成物及びその使用方法
JP2015503593A5 (enExample)
JP2014525465A5 (enExample)
JP2013529665A5 (enExample)
JP2016522188A5 (enExample)
Mantovani Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
JP2017502996A (ja) 絶食条件下でのタシメルテオンの投与
JP2017514858A5 (enExample)
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2016539149A5 (enExample)
CN112823795A (zh) 一种特发性肺纤维化药物组合及其应用
RU2016136666A (ru) Составы на основе прогестерона
Teng et al. Neuroprotection of maslinic acid, a novel glycogen phosphorylase inhibitor, in type 2 diabetic rats
CN105050607B (zh) 用于治疗关节炎和骨关节炎的方法和组合物
JP2023549522A5 (enExample)
JP2016514142A5 (enExample)
JP2009263384A (ja) I型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬
Elleuch et al. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma
Koike Interstitial pneumonia: 8 case reports